The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL
Phase 4
Completed
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Biological: Pneumococcal polysaccharide vaccine (PPV)
- Registration Number
- NCT00919321
- Lead Sponsor
- Tampere University Hospital
- Brief Summary
Patients with chronic lymphocytic leukemia (CLL)have had very poor humoral responses to pneumococcal polysaccharide vaccine (PPV). The vaccine in which pneumococcal polysaccharide antigens are conjugated to protein (PCV) have been immunogenic in CLL patients in our previous studies.
The purpose of this study is to evaluate the duration of these vaccine-induced antibodies and the function of memory cells by giving a one dose of PPV-vaccine after several years of PCV-vaccination.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
- CLL patients and controls who have been vaccinated with PCV in our previous study
Exclusion Criteria
- Vaccinated with PPV-vaccine within the last 5 years, immunoglobulin substitution, corticosteroid treatment (equivalent of 20mg prednisolone per day)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PPV Pneumococcal polysaccharide vaccine (PPV) -
- Primary Outcome Measures
Name Time Method Antibody response 1-3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tampere University Hospital
🇫🇮Tampere, Finland